Key Takeaways
- • Pharma and biotech dealmaking surged in H1 2026, with $134 billion in transaction volume, exceeding the full-year 2025 total of $112 billion and marking an acceleration in consolidation activity across the sector.
- • Private equity deal activity in pharmaceutical supply chain services declined 15% annually between 2021–2023, reaching ~180 deals in 2024, but the $77 billion global pharma supply chain services market presents high-growth opportunities in raw materials and consumables subsegments.
- • Active pharmaceutical ingredients (APIs) and pharmaceutical manufacturing are emerging as primary PE investment targets, driven by novel drug creation, reshoring sentiment, and regulatory support for domestic production capacity.
- • 33 biotech acquisitions were completed in the first half of 2026, reflecting large pharmaceutical players' acceleration of M&A to offset an estimated $300 billion-plus cliff of branded drug patent expirations.
- • US legislation is increasing scrutiny of biopharmaceutical development deals with Chinese manufacturers, signaling heightened geopolitical and regulatory constraints on cross-border pharma dealmaking.
Summary
Pharmaceutical and biotech dealmaking has entered a robust cycle in 2026, with the first six months generating $134 billion in transaction volume—a substantial increase over 2025's full-year total of $112 billion. This acceleration reflects large pharmaceutical companies deploying capital aggressively to address an estimated $300 billion-plus cliff of patent expirations on branded drugs. The flurry of activity includes 33 biotech acquisitions, signaling consolidation across the innovation pipeline as established players seek to replenish their portfolios through external growth.
Despite this near-term momentum, the underlying landscape for private equity in pharma services remains challenged. McKinsey research indicates that PE deal activity in pharmaceutical supply chain services fell 15 percent annually between 2021 and 2023, with deal count contracting to approximately 180 transactions in 2024—a steep decline from the pandemic-era peak of roughly 340 deals in 2020. Investment capital deployed in the sector has been equally volatile, plummeting from nearly $50 billion in 2021 to $6 billion by fall 2024. However, the global pharma supply chain services industry maintains a $77 billion profit pool, with high-growth subsegments such as raw materials, consumables, and active pharmaceutical ingredients (APIs) presenting targeted opportunities for PE investors.
Manufacturing infrastructure and API production have emerged as distinct PE dealmaking themes this week and quarter. Novel drug creation and product development are fueling demand for API investments, while domestic pharmaceutical manufacturing capacity has gained strategic importance amid reshoring trends and regulatory support. The Economic Development Administration (EDA) is actively supporting pharmaceutical manufacturing expansion, with at least one company planning to invest over $1.3 million and create 130 new jobs in manufacturing capacity. Additionally, several manufacturing-focused capital partners are actively funding independent sponsor deals in the sector, signaling institutional conviction in the subsegment.
Regulatory headwinds are shaping deal parameters, particularly around cross-border transactions. New US legislation targeting US-China dealmaking in biopharmaceutical development reflects growing scrutiny of foreign supply chain dependencies and geopolitical risk management. This legislative environment is likely to constrain certain acquisition pathways while simultaneously creating deal opportunities in domestic manufacturing consolidation and supply chain resilience plays.
Despite this near-term momentum, the underlying landscape for private equity in pharma services remains challenged. McKinsey research indicates that PE deal activity in pharmaceutical supply chain services fell 15 percent annually between 2021 and 2023, with deal count contracting to approximately 180 transactions in 2024—a steep decline from the pandemic-era peak of roughly 340 deals in 2020. Investment capital deployed in the sector has been equally volatile, plummeting from nearly $50 billion in 2021 to $6 billion by fall 2024. However, the global pharma supply chain services industry maintains a $77 billion profit pool, with high-growth subsegments such as raw materials, consumables, and active pharmaceutical ingredients (APIs) presenting targeted opportunities for PE investors.
Manufacturing infrastructure and API production have emerged as distinct PE dealmaking themes this week and quarter. Novel drug creation and product development are fueling demand for API investments, while domestic pharmaceutical manufacturing capacity has gained strategic importance amid reshoring trends and regulatory support. The Economic Development Administration (EDA) is actively supporting pharmaceutical manufacturing expansion, with at least one company planning to invest over $1.3 million and create 130 new jobs in manufacturing capacity. Additionally, several manufacturing-focused capital partners are actively funding independent sponsor deals in the sector, signaling institutional conviction in the subsegment.
Regulatory headwinds are shaping deal parameters, particularly around cross-border transactions. New US legislation targeting US-China dealmaking in biopharmaceutical development reflects growing scrutiny of foreign supply chain dependencies and geopolitical risk management. This legislative environment is likely to constrain certain acquisition pathways while simultaneously creating deal opportunities in domestic manufacturing consolidation and supply chain resilience plays.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.